Related Experiment Videos
Oligonucleotide analogues as potential chemotherapeutic agents
1Applied Biosystems, Foster City, California 94404.
Pharmaceutical Research
|September 1, 1988
Summary
Short DNA/RNA sequences (oligonucleotides) can target specific genes for novel drug design. Modified oligonucleotides resist degradation, enabling therapeutic applications like antisense inhibition.
Area of Science:
- Molecular Biology
- Medicinal Chemistry
- Biotechnology
Background:
- Oligonucleotides bind to complementary DNA/RNA sequences via hydrogen bonds.
- Short oligonucleotides (<20 bases) can specifically hybridize DNA/RNA.
- Targeted interference of genetic expression offers novel drug design strategies.
Purpose of the Study:
- Review research on oligonucleotide analogues for therapeutic applications.
- Classify structures and mechanisms of action for antisense inhibition.
- Summarize biological studies and pharmaceutically relevant topics.
Main Methods:
- Utilizing automated synthesis for modified oligonucleotides.
- Employing modified internucleoside linkages (methylphosphonates, phosphorothioates).
- Incorporating modified nucleosides (2 -0-methylribose, alpha-anomers).
Main Results:
- Nuclease-resistant oligonucleotide analogues are readily available.
- Pendant groups (alkylating, intercalating agents) enhance analogue efficacy.
- Various structures and mechanisms of action are classified.
Conclusions:
- Modified oligonucleotides are promising for antisense inhibition therapies.
- Chemical modifications enhance stability and efficacy for drug design.
- Further research in stereochemistry and biological studies is warranted.